Curium agrees to buy Lantheus for USD 102.5 a share plus CVR of up to USD 12

PUBT · 1d ago
Curium agrees to buy Lantheus for USD 102.5 a share plus CVR of up to USD 12
  • Curium US agreed to buy Lantheus for USD 102.5 per share in cash at closing.
  • Deal includes non-transferable CVRs worth up to USD 12 per share, tied to commercial milestones through 2030; total consideration up to USD 114.5.
  • Implied transaction value up to about USD 8 billion; expected to close in H1 2027, pending shareholder and regulatory approvals.
  • Combination pairs Curium’s theranostics portfolio and manufacturing platform with Lantheus’ US radiodiagnostics franchise.
  • Lantheus is expected to delist on completion; it will operate independently until closing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030731PRIMZONEFULLFEED9802402) on August 03, 2026, and is solely responsible for the information contained therein.